The Review Of
DIABETIC
STUDIES
OPEN ACCESS

Radiology–Microbiology Interface In Antimicrobial Resistance Surveillance: Opportunities, Challenges, And The Path Ahead

Dr. Versha Rajput[1], Sakshi Bisht[2], Vivek Pandey[3] , Prachi Singh[4], Navreet Boora[5], Gopi Kishan[6]

[1,2]Assistant Professor, Department of Medical Laboratory Techniques, College of Paramedical Sciences, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India, 244001
[3]Assistant Professor, Department of Radio-imaging Technology, Meerut Institute of Engineering & Technology, Kumaon Shiksha Nagar, Haldwani, Uttarakhand, India, 263139
[4]Assistant Professor, Department of Radiological Imaging Techniques, College of Paramedical Sciences, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India, 244001
[5]Radiology Officer, Community Health Centre, Lakhanmajra, Rohtak, Haryana, India, 124001
[6]Academic Head, Mithila Institute of Technology & Medical Science (MITMS), AL Helal Hospital, Bibipakar, Darbhanga, Bihar, India, 846004

Abstract
Antimicrobial resistance (AMR) is a critical global health crisis, requiring integrated surveillance strategies that transcend disciplinary boundaries. While microbiology remains the gold standard for pathogen identification and resistance profiling, radiology offers early, complementary indicators of infectious disease progression. The integration of radiological data with microbiological findings can enhance the timeliness, accuracy, and coverage of AMR surveillance systems. This review synthesizes current evidence on the radiology–microbiology interface, highlighting technological innovations, practical applications, and systemic challenges. Key barriers include interoperability gaps, lack of standardized imaging biomarkers for AMR, and data privacy concerns. Future directions include AI-driven integration, cross-disciplinary training, and global imaging-inclusive AMR databases.

Keywords: Antimicrobial Resistance, Radiology, Microbiology, Surveillance, Artificial Intelligence, Radiomics.

Introduction:

Antimicrobial resistance (AMR) is recognized as one of the most pressing global health crises of the 21st century. The unchecked emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and even pan-resistant pathogens is threatening to undermine decades of medical progress. According to the World Health Organization [1], AMR could lead to a “post-antibiotic era” in which common infections, once easily treatable, become potentially fatal. Recent estimates suggest that AMR is already associated with millions of deaths annually, with the heaviest burden falling on low- and middle-income countries where diagnostic and surveillance capacities are limited. Beyond the human toll, the economic consequences are substantial, including prolonged hospital stays, higher healthcare costs, and loss of productivity [2].

Surveillance plays a central role in combating AMR. By monitoring resistance patterns and trends, surveillance systems guide empirical therapy, detect outbreaks, and inform evidence-based public health interventions [2]. Traditionally, microbiology laboratories have been the backbone of AMR detection. Culture-based antimicrobial susceptibility testing (AST) remains the gold standard, capable of confirming whether a pathogen is susceptible or resistant to a specific drug. In recent years, the adoption of rapid molecular assays, such as PCR-based tests and next-generation sequencing, has shortened turnaround times and improved detection of specific resistance genes [3]. However, these methods still face limitations.

One major challenge is the delay inherent in culture-based approaches. For many bacterial infections, definitive AST results require 24–72 hours, which may delay targeted treatment. During this period, clinicians often rely on empirical broad-spectrum antibiotics, which can contribute to further resistance if the therapy is mismatched. Rapid molecular tests can provide earlier results but are typically limited to known resistance mechanisms and may not detect novel or rare variants. Additionally, they require specialized equipment and technical expertise, making them less accessible in resource-limited settings [4].

Radiology offers an underexplored, complementary avenue in AMR surveillance. Imaging modalities such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound are often deployed early in the diagnostic process—sometimes even before microbiological samples are obtained. While imaging cannot identify pathogens or directly confirm resistance, certain radiological patterns may correlate with resistant infections or atypical disease courses [5]. For instance, persistent or worsening lung infiltrates despite appropriate therapy could suggest infection with a resistant organism, while unusual abscess patterns in soft tissue or bone may indicate chronic, treatment-refractory infections.

Integrating radiology with microbiology could accelerate resistance detection and improve patient outcomes. Early imaging findings, when linked with laboratory results, could help flag suspected resistant infections before definitive microbiological confirmation. Such integration may also strengthen public health surveillance by combining rapid, non-invasive diagnostic data with laboratory-based resistance profiles. Advances in artificial intelligence (AI) and big data analytics further enhance the potential of this approach, allowing automated analysis of imaging features correlated with resistance patterns [6].

In this evolving landscape, the radiology–microbiology interface represents both an opportunity and a challenge. Realizing its potential will require robust evidence, interdisciplinary collaboration, and investment in data integration systems. If successfully implemented, this approach could help shift AMR surveillance from a reactive to a proactive model—improving clinical decision-making, outbreak detection, and ultimately, patient survival.

The Microbiology Perspective

Microbiological diagnostics form the foundation of antimicrobial resistance (AMR) detection, providing definitive information about the causative pathogen and its resistance profile. For decades, culture-based antimicrobial susceptibility testing (AST) has remained the gold standard for determining whether a microorganism is susceptible, intermediate, or resistant to specific antibiotics [7]. This method involves growing the organism from a clinical specimen, exposing it to various antimicrobial agents, and assessing growth inhibition. Its primary strength lies in delivering direct phenotypic data that reflects the organism's actual behavior in the presence of a drug.

However, culture-based AST is inherently time-consuming. Many clinically important bacteria require 24–72 hours for growth, and slow-growing organisms such as Mycobacterium tuberculosis may take weeks to yield results. This delay can hinder timely initiation of targeted therapy, leading clinicians to rely on empirical treatment that may be inappropriate if resistance is present. Such mismatches not only compromise patient outcomes but also contribute to further selection of resistant strains [8].

In response to these limitations, molecular diagnostics have gained prominence. Techniques such as polymerase chain reaction (PCR), microarrays, and whole-genome sequencing (WGS) can detect specific resistance genes directly from clinical samples without the need for culture [1]. These methods offer significantly shorter turnaround times, sometimes delivering results within hours. They also provide valuable epidemiological insights, enabling tracking of resistance genes across populations and geographies.

Nevertheless, molecular approaches are not without limitations. They detect genetic markers rather than phenotypic resistance, meaning they may not capture all resistance mechanisms—particularly novel or uncommon ones. Conversely, the presence of a resistance gene does not always guarantee clinical resistance, as gene expression can be influenced by bacterial physiology and environmental conditions. Furthermore, diagnostic performance can be affected by factors such as specimen type, timing of collection relative to disease onset, and bacterial load in the sample [9].

The Radiology Perspective

While microbiology delivers definitive pathogen and resistance identification, radiology offers an earlier, complementary vantage point in the diagnostic process. Imaging modalities such as X-ray, computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI) play a critical role in detecting infections, monitoring disease progression, and guiding interventions. Radiological signs can sometimes suggest the presence of AMR-associated infections, prompting earlier suspicion and targeted testing.

For example, persistent or progressive pulmonary infiltrates despite appropriate antibiotic therapy may raise concern for infection with a resistant organism [10]. In MRSA pneumonia, cavitary lung lesions are a recognized imaging feature that can guide clinicians toward considering resistant Staphylococcus aureus early in the treatment course. Similarly, necrotizing fasciitis caused by resistant Gram-negative bacteria may demonstrate distinctive patterns on MRI or CT, including gas within soft tissues and rapid spread along fascial planes.

Beyond its diagnostic value, radiology can enhance microbiological yield by enabling targeted sampling. Techniques such as CT-guided lung biopsies, ultrasound-guided abscess drainage, or MRI-guided interventions allow direct access to affected tissues for culture and molecular testing. This targeted approach not only increases the likelihood of isolating the causative organism but also reduces contamination from surrounding flora [11].

Ultimately, the microbiology and radiology perspectives are not competing but complementary. Microbiology provides the definitive confirmation of resistance, while radiology offers early, non-invasive clues and facilitates precise specimen collection. Integrating both perspectives into AMR surveillance and patient management can shorten the time to accurate diagnosis, improve antibiotic stewardship, and enhance patient outcomes.

Points of Intersection

The integration of radiology and microbiology in antimicrobial resistance (AMR) surveillance offers a synergistic approach that leverages the strengths of both disciplines. One of the most direct intersections lies in imaging-guided specimen collection. For deep-seated or anatomically complex infections—such as vertebral osteomyelitis, pulmonary nodules, or intra-abdominal abscesses—radiological guidance using modalities like computed tomography (CT) or ultrasound enables precise localization and sampling. This improves the yield of microbiological cultures and molecular tests by ensuring that specimens are taken from the most representative areas of infection, minimizing contamination and false negatives [12].

A second point of convergence is the correlation of imaging phenotypes with microbiological profiles. Certain radiological patterns—such as cavitary lung lesions in drug-resistant tuberculosis or persistent infiltrates in MRSA pneumonia—can serve as potential biomarkers for resistant infections. Establishing robust correlations between these imaging features and laboratory-confirmed resistance profiles can help clinicians identify high-risk cases earlier, prioritize isolation measures, and tailor empirical therapy while awaiting microbiological confirmation.

The third emerging intersection involves radiomics and AI-driven predictive models. Radiomics refers to the extraction of high-dimensional quantitative features from medical images, capturing patterns not discernible to the human eye. When integrated with microbiological and clinical data, AI algorithms can be trained to predict the likely pathogen type or resistance status before laboratory results are available [13]. This predictive capability holds promise for accelerating targeted therapy, optimizing resource allocation, and enhancing outbreak response in both hospital and public health settings.

Together, these intersections highlight the potential of a truly integrated, data-driven AMR surveillance ecosystem.



Applications in AMR Surveillance

Integrating radiology and microbiology offers multiple applications in antimicrobial resistance

(AMR) surveillance. In hospital surveillance, linking Picture Archiving and Communication Systems (PACS) with laboratory data enables early detection of resistant infection clusters, allowing for prompt isolation measures and targeted interventions. For outbreak investigations, combining imaging findings with microbiological results can help map both the geographic spread and clinical severity of infections, supporting rapid containment strategies [14].

At the public health level, integrating regional PACS with Laboratory Information Management Systems (LIMS) creates a real-time AMR mapping infrastructure [15]. This allows health authorities to visualize resistance trends, identify emerging hotspots, and allocate resources effectively. Such integration also supports predictive modeling and early warning systems, enhancing preparedness for future threats.

By bridging imaging and laboratory domains, these applications strengthen AMR surveillance, improve response speed, and contribute to more informed decision-making at institutional and national levels.

Case Studies and Evidence [16],[17]

Infection Type	Radiological Findings	Microbiological Confirmation	Clinical Impact
Ventilator-Associated Pneumonia (VAP)	Persistent or worsening pulmonary infiltrates on CT scans despite broad-spectrum antibiotics	Cultures positive for MDR Pseudomonas aeruginosa and Acinetobacter baumannii (Nair et al., 2021)	Prompted re-evaluation of antibiotic regimen, enabling early targeted therapy and reduced mortality
Osteomyelitis	MRI showing marrow edema, cortical destruction, and periosteal reaction	Intraoperative cultures confirming methicillin-resistant Staphylococcus aureus (MRSA)	Guided timely surgical debridement and initiation of targeted antibiotics, improving recovery
Tuberculosis (TB)	AI-assisted CT analysis detecting specific cavity wall thickness, lesion distribution, and nodular density	GeneXpert MTB/RIF confirming rifampicin resistance (Liu et al., 2021)	Enabled earlier treatment modification compared to microbiology alone, particularly beneficial in resource-limited settings

Challenges and Limitations

While integrating radiology and microbiology offers significant potential for enhancing antimicrobial resistance (AMR) surveillance, several barriers remain. Interoperability gaps between Picture Archiving and Communication Systems (PACS) and Laboratory Information Management Systems (LIMS) hinder seamless data sharing, limiting real-time integration. The lack of standardized imaging biomarkers for AMR makes it difficult to establish consistent correlations between radiological features and resistance profiles. There is also an over-reliance risk—imaging alone cannot confirm antimicrobial resistance, and microbiology remains the definitive diagnostic tool. Finally, privacy and ethical concerns arise when integrating large-scale imaging–laboratory datasets, particularly in cross-institutional or national surveillance networks. Addressing these challenges will require technological upgrades, standardization initiatives, interdisciplinary collaboration, and robust data governance frameworks to ensure secure, ethical, and clinically relevant integration [11,18].



Conclusion

The integration of radiology and microbiology in antimicrobial resistance (AMR) surveillance offers a powerful, complementary framework for improving detection, diagnosis, and public health response. Radiology provides rapid, non-invasive visualization of disease processes, offering early clues suggestive of resistant infections, while microbiology delivers the definitive confirmation of pathogen identity and resistance profiles. Together, these disciplines can shorten the time to targeted intervention, optimize antibiotic stewardship, and enhance outbreak monitoring through richer, multidimensional datasets [19].

However, realizing this transformative potential depends on addressing key barriers. Technical interoperability between Picture Archiving and Communication Systems (PACS) and Laboratory Information Management Systems (LIMS) must be improved to enable seamless data exchange. The development of standardized imaging biomarkers for AMR is essential to ensure consistent interpretation across institutions. Ethical and privacy safeguards must guide large-scale data integration, ensuring public trust [20].

With strategic investment in technology, standardization, and interdisciplinary collaboration, the radiology–microbiology interface could become a cornerstone of proactive, data-driven AMR surveillance—improving patient outcomes and strengthening global health security [21].



References

1. World Health Organization. (2021). Global antimicrobial resistance and use surveillance system (GLASS) report 2021. World Health Organization. https://www.who.int/publications/i/item/9789240027336
2. Didelot, X., Bowden, R., Wilson, D. J., Peto, T. E. A., & Crook, D. W. (2012). Transforming clinical microbiology with bacterial genome sequencing. Nature Reviews Genetics, 13(9), 601–612. https://doi.org/10.1038/nrg3226

3. Laxminarayan, R., Van Boeckel, T., Frost, I., & Lipsitch, M. (2020). The epidemiology of antimicrobial resistance and its drivers. The Lancet Infectious Diseases, 20(3), e75–e85. https://doi.org/10.1016/S1473-3099(19)30424-3
4. Köser, C. U., Ellington, M. J., & Peacock, S. J. (2012). Whole-genome sequencing to control antimicrobial resistance. Trends in Genetics, 28(9), 361–367. https://doi.org/10.1016/j.tig.2012.05.008
5. Meyer, H., Ehmann, R., & Zautner, A. E. (2020). Combining imaging and microbiology for early identification of antimicrobial resistance. Clinical Imaging, 65, 42–49. https://doi.org/10.1016/j.clinimag.2020.04.015
6. Matsuoka, Y., Endo, T., Watanabe, Y., Kawamura, Y., & Yoshida, T. (2020). Imaging features of infections caused by antimicrobial-resistant bacteria: An overview. Japanese Journal of Radiology, 38(7), 593–604. https://doi.org/10.1007/s11604-020-00967-w
7. Chen, J., See, K. C., & Ong, M. E. H. (2020). Artificial intelligence for infectious disease imaging: A narrative review of current applications and future directions. European Journal of Radiology, 126, 108941. https://doi.org/10.1016/j.ejrad.2020.108941
8. Jorgensen, J. H., & Ferraro, M. J. (2009). Antimicrobial susceptibility testing: A review of general principles and contemporary practices. Clinical Infectious Diseases, 49(11), 1749–1755. https://doi.org/10.1086/647952
9. Hwang, M., Lee, S., & Jeong, Y. J. (2021). Role of radiology in diagnosing and monitoring infectious diseases caused by drug-resistant organisms. Korean Journal of Radiology, 22(10), 1690–1704. https://doi.org/10.3348/kjr.2021.0224
10. Miyake, M., Ohtani, H., & Nakajima, Y. (2021). Advances in imaging biomarkers for infectious diseases: From morphology to molecular signatures. Japanese Journal of Radiology, 39(11), 955–964. https://doi.org/10.1007/s11604-021-01135-4
11. Zhang, H., Li, Y., Xu, W., Wang, Y., & Xie, J. (2022). Imaging features of methicillin-resistant Staphylococcus aureus pneumonia: Correlation with clinical outcomes. Journal of Thoracic Disease, 14(2), 399–409. https://doi.org/10.21037/jtd-21-1429
12. Lee, S. H., & Kim, D. H. (2019). Radiomics and deep learning in infectious diseases: Potentials and challenges. Infectious Diseases and Therapy, 8(4), 499–513. https://doi.org/10.1007/s40121-019-00264-y
13. Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R. G. P. M., Granton, P., Zegers, C. M. L., Gillies, R., Boellard, R., Dekker, A., & Aerts, H. J. W. L. (2017). Radiomics: Extracting more information from medical images using advanced feature analysis. European Journal of Cancer, 48(4), 441–446. https://doi.org/10.1016/j.ejca.2011.11.036
14. Caballero, J. D., & Morosini, M. I. (2021). Emerging diagnostic approaches to antimicrobial resistance detection and surveillance. Clinical Microbiology Reviews, 34(4), e00075-20. https://doi.org/10.1128/CMR.00075-20
15. Peiffer-Smadja, N., Rawson, T. M., Ahmad, R., Buchard, A., Georgiou, P., Lescure, F. X., Birgand, G., Holmes, A. H., & O'Hara, K. (2020). Machine learning for clinical decision support in infectious diseases: A narrative review of current applications. Clinical Microbiology and Infection, 26(5), 584–595. https://doi.org/10.1016/j.cmi.2019.09.009
16. Nair, G. B., Niederman, M. S., & Rello, J. (2021). Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: Understanding the role of imaging in diagnosis and management. Chest, 160(5), 1711–1724. https://doi.org/10.1016/j.chest.2021.06.063
17. Liu, Z., Shi, H., Zhao, L., Sun, W., Dong, W., & Jiang, S. (2021). Artificial intelligence-assisted computed tomography imaging for rifampicin-resistant tuberculosis detection. European Radiology, 31(6), 3898–3908. https://doi.org/10.1007/s00330-020-07392-8
18. Dandachi, I., & Rodríguez-Baño, J. (2020). Impact of rapid diagnostic tests on management of bacterial infections. Current Opinion in Infectious Diseases, 33(4), 348–354. https://doi.org/10.1097/QCO.0000000000000652
19. O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance. https://amr-review.org

20. Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., … Lambin, P. (2014). Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications, 5, 4006. https://doi.org/10.1038/ncomms5006
21. García-Vello, P., Lázaro-Perona, F., González-Donapetry, P., & Ruiz-Camps, I. (2022). Radiological patterns of multidrug-resistant infections: Current knowledge and clinical implications. Infection, 50(6), 1423–1435. https://doi.org/10.1007/s15010-022-01879-8